LeonaBio (LONA) Common Equity (2019 - 2026)

LeonaBio (LONA) has 8 years of Common Equity data on file, last reported at $49.3 million in Q1 2026.

• Quarterly Common Equity rose 32.07% year-over-year to $49.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.3 million (up 32.07% YoY) and the FY2025 annual result came in at $27.8 million, down 38.03% from the prior year.
• Common Equity advanced to $49.3 million in Q1 2026 per LONA's latest filing, from $27.8 million in the prior quarter.
• Across five years, Common Equity topped out at $302.0 million in Q1 2022 and bottomed at $26.8 million in Q3 2025.
• The 5-year median for Common Equity is $106.7 million (2024), against an average of $131.0 million.
• The widest annual swing landed in 2024, when Common Equity tumbled 65.56%; it then surged 32.07% in 2026.
• Tracing LONA's Common Equity over 5 years: stood at $235.1 million in 2022, then sank by 44.63% to $130.2 million in 2023, then plunged by 65.56% to $44.8 million in 2024, then sank by 38.03% to $27.8 million in 2025, then jumped by 77.41% to $49.3 million in 2026.
• Per Business Quant, the three latest LONA Common Equity figures stand at $49.3 million (Q1 2026), $27.8 million (Q4 2025), and $26.8 million (Q3 2025).

Peer Comparison